Brief Introduction

Established in 2000,Bloomage Biotech is an international company dedicated to the development and application of microbiome, with our core technology rooted in the Fermentation and Cross-link technologies. Bloomage portfolio covers the upstream and downstream value chain of Hyaluronic Acid(HA), from raw materials to end products.Its market share of raw material is 36% globally.B2B2C and B2C Products include medical aesthetics, intra-articular injectable products, health foods, and functional skincare range. Bloomage Biotech with worldclass quality management system has 20 years of R&D and regulatory experience.

Company Overview

Full name Bloomage Biotechnology Corporation Limited
Abbreviations Bloomage Biotech
Code 688363
Founded 2000.1.3
Listing 2019.11.6
Domicile Jinan, Shandong
Website http://www.bloomagebiotech.com/
Email ir@bloomagebiotech.com
STAR Theme Biomedicine
CSRCSector Pharmaceutical manufacturing(C27)
Has weighted voting rights structure? No

Financials

Highlights

  2018 2017 2016
Earnings Per Share - - -
R&D expenditure as a % of operating revenue 4.19% 3.14% 3.27%
Operating Revenue 1,263 818 733
Net Income 424 222 269

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 1,263 818 733
Operating Costs 254 201 166
Operating Income 524 284 320
Pretax Income 515 284 330
Income Tax 91 62 60
Net Income 424 222 269

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Assets
Current Assets-Total 1,297 1,170 981
Non-current Assets-Total 774 713 703
Total Assets 2,071 1,883 1,684
Liabilities
Current Liabilities-Total 291 182 383
Non-current Liabilities-Total 62 64 41
Total Liabilities 354 245 424
Stockholder's Equity
Share Capital 1,238 576 409
Retained Profits 480 1,062 852
Total Owners' Equity 1,717 1,638 1,261

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 442 343 242
Net Cash Flows-Investing -35 -329 -18
Net Cash Flows-Financing 85 -231 208

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
华熙昕宇投资有限公司 283.50 59.06%
国寿成达(上海)健康产业股权投资中心(有限合伙) 34.43 7.17%
宁夏赢瑞物源股权投资合伙企业(有限合伙) 33.09 6.89%
Fortune Ace Investment Limited 7.75 1.62%
中金佳泰贰期(天津)股权投资基金合伙企业(有限合伙) 7.17 1.49%
天津华杰海河医疗投资合伙企业(有限合伙) 6.60 1.37%
艾睿思(天津)医疗投资合伙企业(有限合伙) 6.31 1.32%
中国民生信托有限公司 5.83 1.21%
WEST SUPREME LIMITED 5.77 1.20%
Luminescence (Hong Kong) Co., Limited 5.01 1.04%
05 Nov 2019

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.